Synthetic Anti-Biofilm Peptide (07028)
- *Abstract
-
Features and Benefits
- May prevent bacterial adhesion to abiotic surfaces
- May prevent biofilm formation in human/animal tissues
- May enhance effects of antibiotics
- May have low toxicity in humans, giving it separation from other biofilm inhibitors that are more toxic and unsafe in humans
*This Technology is available for licensing, further development, or industrial partnering*
Technology
Researchers at the University of Louisville have discovered a family of peptides that may be able to be "tuned" to prevent biofilm formation, agglutinate bacteria, or kill existing bacteria, specifically P. aeruginosa. The peptides are based on the sequences of human Parotid Secretory Protein and have been observed inhibiting biofilm formation while not eliminating established biofilm.
Markets Addressed
Biofilms are estimated to cause the majority of all infections, including urinary tract infections, catheterization-related infections, infections in cystic fibrosis, as well as some permanent infections in heart valves. Bacteria in biofilms are also very difficult to eradicate due to their antibiotics resistance. These novel peptides should work in part by increasing the agglutination and killing of bacteria while reducing inflammation. Use of the technology may enhance the effects of antibiotics when used together. Use of the technology may also be ideal in situations where resistance to antibiotics is a concern. Because the technology is based off a human protein it is expected to have low toxicity to humans.
Technology Status
- IP Status: Issued
- US PatentDevelopment Status: Further Development needed. Shown effective in lettuce leaf model
- Fields of Use Available: All
- Country/Region
- USA
